Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Biologic therapy. University Hospital Gasthuisberg, Leuven, Belgium

Survival: 6.3 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: Belgium
City/State/Province: Leuven
Hospital: University Hospital Gasthuisberg
Journal: Link
Date: 1/2008

Patients: This phase III study involved 176 patients with metastatic colorectal cancer. The median age was sixty-two, ranging from 32 to 83 years old. These patients had received from 2 to 6 prior treatments with chemotherapy.

Treatment: Patients were treated with panitumumab, a biological therapy.

Toxicity: Three patients had grade 4 toxicities: acute renal failure, pulmonary embolism, erythema, and pustular acne. Grade 3 toxicities was reported in 16% of the patients. Erythema and acne were the most common toxicity of any grade, occurring in 64 and 59% of patients, respectively.

Results: The median overall survival was 6.3 months.

Support: This study was supported by Amgen, Inc., which developed panitumumab and markets it under the name Vectibix.

Correspondence: Dr. E. Van Cutsem

E-mail to a Friend Email Physician More Information